Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-30 00:45:20 - browse：738

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medtronic CEO on promising devices for diabetes, hypertension

knowledge

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

STAT Virtual Event: The State of Biosimilars: What to Watch

Biden's order seeks to regulate AI risk without stifling innovation

Testing for cancer recurrence creates a new limbo for patients

Testing for cancer recurrence creates a new limbo for patients

First Opinion Podcast: How to protect health care in times of war

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

The high cost of giving birth even with insurance

How dance can help nurses traumatized by Covid

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medicare to cover more brain scans for Alzheimer’s patients

Wildfire smoke exposes gaps in outdoor worker protections

Sanders adds drug shortage policies to pandemic preparedness bill

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sanofi seeks simpler, safer CRISPR sickle cell cure

BioMarin wins approval for gene therapy to treat hemophilia A

Cassava reveals details — and problems — with Alzheimer's study

Wikipedia

Testing for cancer recurrence creates a new limbo for patients

Readout Newsletter: What happened with Sarepta's Duchenne data

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Why hospitals are withdrawing from US News rankings

Telehealth options flood the market as retailers push virtual care

How Medicaid coverage policies for immigrants impact new moms

knowledge

leisure time

hotspot

explore